Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Blueshift Asset Management LLC

Blueshift Asset Management LLC trimmed its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 37.1% during the fourth quarter, HoldingsChannel reports. The firm owned 154,091 shares of the company’s stock after selling 90,922 shares during the period. Hims & Hers Health comprises about 1.4% of Blueshift Asset Management LLC’s investment portfolio, making the stock its 4th biggest holding. Blueshift Asset Management LLC’s holdings in Hims & Hers Health were worth $3,726,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in HIMS. Crewe Advisors LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $28,000. Raleigh Capital Management Inc. increased its holdings in shares of Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares during the last quarter. Blume Capital Management Inc. raised its position in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 600 shares during the period. Smartleaf Asset Management LLC grew its position in Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after acquiring an additional 1,413 shares during the period. Finally, US Bancorp DE increased its stake in Hims & Hers Health by 346.7% during the fourth quarter. US Bancorp DE now owns 1,943 shares of the company’s stock worth $47,000 after acquiring an additional 1,508 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Trading Up 7.5 %

Shares of HIMS opened at $33.85 on Thursday. The firm has a market capitalization of $7.52 billion, a price-to-earnings ratio of 76.94 and a beta of 1.37. The firm’s fifty day simple moving average is $38.88 and its 200-day simple moving average is $28.52. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. On average, analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HIMS has been the topic of several recent analyst reports. BTIG Research started coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Morgan Stanley downgraded shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $42.00 to $60.00 in a report on Tuesday, February 18th. Leerink Partners upped their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 25th. Truist Financial lifted their price objective on Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a research note on Wednesday, February 26th. Finally, Needham & Company LLC increased their target price on Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Hims & Hers Health has an average rating of “Hold” and an average target price of $37.31.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 18,959 shares of the firm’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $25.77, for a total transaction of $488,573.43. Following the transaction, the chief financial officer now owns 132,578 shares of the company’s stock, valued at approximately $3,416,535.06. This trade represents a 12.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Michael Chi sold 7,259 shares of Hims & Hers Health stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $24.07, for a total value of $174,724.13. Following the sale, the insider now owns 193,601 shares in the company, valued at $4,659,976.07. This trade represents a 3.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,034,506 shares of company stock worth $36,635,024 over the last three months. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.